Uromigos-Prostate Cancer

Advertisement
The UromigosThe Uromigos | June 10, 2024
Drs. Nobuaki Matsubara, Hiroshi Kitamura and Yuji Miura answer trivia questions set by Tom and Brian for the Uromigos Cup.
Listen Now
The UromigosThe Uromigos | June 6, 2024
Dr. Alex Wyatt describes the predictive capabilities of ctDNA in determining outcomes in the TheraP trial.
The UromigosThe Uromigos | June 6, 2024
Dr. Christos Kyriakopoulos describes the outcome of the CHAARTED-2 study for castration-resistant prostate cancer.
The UromigosThe Uromigos | May 30, 2024
Drs. Danny Heng, Christian Kollmannsberger and Kala Sridhar attempt to take on Team LA to win the Uromigos Cup.
The UromigosThe Uromigos | June 6, 2024
Silke Gillessen joins Brian and Tom to give a preview of this year's ASCO annual meeting.
The UromigosThe Uromigos | June 3, 2024
Dr. Nick James joins the podcast to discuss the recent Lancet Commission paper on prostate cancer.
The UromigosThe Uromigos | April 30, 2024
Dr. Silke Gillessen gives a summary of APCCC 2024, including surgery versus RT, genetic and somatic testing, and more.
The UromigosThe Uromigos | May 24, 2024
Chris Sweeney is joined by fellow experts to discuss mHSPC side effects such as bone weakness, hot flashes, and gynecomastia.
The UromigosThe Uromigos | April 30, 2024
Professor Thomas Suter and Dr. Chuck Ryan discuss cardiovascular risks associated with hormone therapy in prostate cancer.
The UromigosThe Uromigos | April 30, 2024
Drs. Thomas Zilli and Pierre Blanchard debate the use of radiation therapy in prostate cancer and oligometastatic disease.
The UromigosThe Uromigos | April 30, 2024
Brian and Tom speak with Drs. Piet Ost and Jason Efstathiou on the data for and against radiation therapy in prostate cancer.
The UromigosThe Uromigos | April 18, 2024
Daniel Goldstein returns to the podcast to discuss dosing changes in drugs such as nivolumab and pembrolizumab.
The UromigosThe Uromigos | April 18, 2024
FDA Deputy Oncology Director Dan Suzman describes approaches to oncology trials in the GU setting.
The UromigosThe Uromigos | March 14, 2024
Dr. Tanya Dorff discusses her work on a phase 1 study investigating acapatamab for advanced prostate cancer.
The UromigosThe Uromigos | March 8, 2024
Michael Lattanzi, MD, joins the podcast to discuss treatment plans and research in the community oncology setting.
The UromigosThe Uromigos | February 26, 2024
Vania Wisdom, Senior Executive Editor at The Lancet, discusses cancer treatment and research in developing countries.
The UromigosThe Uromigos | February 7, 2024
Dr. Dana Rathkopf describes the phase 1 data for the androgen receptor ligand-directed degrader in prostate cancer.
The UromigosThe Uromigos | January 30, 2024
Dr. Agarwal discusses the CONTACT-02 trial that analyzed the use of cabozantinib in combination with atezolizumab for mCRPC.
The UromigosThe Uromigos | January 30, 2024
Dr. Kim Chi discusses the BRCAAway and CONTACT-02 trials presented at ASCO GU 2024.
The UromigosThe Uromigos | January 30, 2024
Dr. Himisha Beltran, describes the activity of novel agent HPN328 in neuroendocrine prostate cancer.
Advertisement
Advertisement
Advertisement